Literature DB >> 21349401

Cardiovascular events in patients with fabry disease natural history data from the fabry registry.

Manesh R Patel1, Franco Cecchi, Marta Cizmarik, Ilkka Kantola, Ales Linhart, Kathy Nicholls, Jörg Strotmann, Jose Tallaj, Thi Chien Tran, Michael L West, Dana Beitner-Johnson, Ademola Abiose.   

Abstract

OBJECTIVES: These analyses were designed to determine the incidence of major cardiovascular (CV) events and the natural history of CV complications in patients with Fabry disease.
BACKGROUND: Fabry disease, a genetic disorder caused by deficiency of alpha-galactosidase A activity, is associated with CV dysfunction.
METHODS: Major CV events (myocardial infarction, heart failure, or cardiac-related death) were analyzed in 2,869 Fabry Registry patients during the natural history period (i.e., before enzyme replacement therapy or among patients who never received therapy). Multivariate logistic regression analyses were performed to identify significant predictors of CV events.
RESULTS: Eighty-three of 1,424 men (5.8%) and 54 of 1,445 women (3.7%) experienced CV events at mean ages of 45 and 54 years, respectively. Heart failure was the most common first CV event, reported by 50 men (3.5%) and 33 women (2.3%). Hypertension and left ventricular hypertrophy were the risk factors most strongly associated with CV events. When these parameters were used as covariates in logistic regression analyses, the odds ratio (OR) for hypertension in men was 7.8 (95% confidence interval [CI]: 2.1 to 28.6, p = 0.0019), and the OR for hypertension in women was 4.5 (95% CI: 1.6 to 12.3, p = 0.0037). The OR for left ventricular hypertrophy was 4.8 in men (95% CI: 1.03 to 22.2, p = 0.0463) and 8.2 in women (95% CI: 2.6 to 26.0, p = 0.0003).
CONCLUSIONS: Major CV events occurred in approximately 5% of Fabry Registry patients during the natural history period. All patients with Fabry disease should be monitored for possible CV risk factors, particularly hypertension and left ventricular hypertrophy.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21349401     DOI: 10.1016/j.jacc.2010.11.018

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  36 in total

Review 1.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.

Authors:  Saskia M Rombach; Bouwien E Smid; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  J Inherit Metab Dis       Date:  2014-02-04       Impact factor: 4.982

Review 2.  Clinical applications of multiparametric CMR in left ventricular hypertrophy.

Authors:  Sabrina Nordin; Luke Dancy; James C Moon; Daniel M Sado
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-03       Impact factor: 2.357

3.  Early cardiac changes in children with anderson-fabry disease.

Authors:  Stepan Havranek; Ales Linhart; Zuzana Urbanova; Uma Ramaswami
Journal:  JIMD Rep       Date:  2013-04-02

4.  Arrhythmias in Fabry cardiomyopathy.

Authors:  Deepak Acharya; Peter Robertson; G Neal Kay; Leslie Jackson; David G Warnock; Vance J Plumb; José A Tallaj
Journal:  Clin Cardiol       Date:  2012-08-09       Impact factor: 2.882

5.  Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease.

Authors:  Letizia Spinelli; Teresa Pellegrino; Antonio Pisani; Caterina Anna Giudice; Eleonora Riccio; Massimo Imbriaco; Marco Salvatore; Bruno Trimarco; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-07       Impact factor: 9.236

6.  Anderson-Fabry disease: Worthy to in-SPECT the nerves?

Authors:  Samia Massalha; Riemer H J A Slart
Journal:  J Nucl Cardiol       Date:  2019-06-19       Impact factor: 5.952

7.  Quantification of myocardial deformation in patients with Fabry disease by cardiovascular magnetic resonance feature tracking imaging.

Authors:  Lei Zhao; Chen Zhang; Jie Tian; Madiha Saiedi; Chenyao Ma; Ning Li; Fang Fang; Xiaohai Ma; Joseph Selvanayagam
Journal:  Cardiovasc Diagn Ther       Date:  2021-02

Review 8.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

9.  A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease.

Authors:  Rebecca Kozor; Fraser Callaghan; Michel Tchan; Christian Hamilton-Craig; Gemma A Figtree; Stuart M Grieve
Journal:  J Cardiovasc Magn Reson       Date:  2015-02-21       Impact factor: 5.364

10.  Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.

Authors:  Saskia M Rombach; Bouwien E Smid; Machtelt G Bouwman; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  Orphanet J Rare Dis       Date:  2013-03-25       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.